 Actinium Pharmaceuticals, Inc.s results from the phase 3 SIERRA trial, using Iomab-B as a preconditioning agent in patients over the age of 55 with active relapsedrefractory AML are expected Q4 of 2022. Prior study shows that 100 of patients who received Iomab-B were able to go on to receive BMT and engraftment without any type of delay. 